| Budget Amount *help |
¥18,980,000 (Direct Cost: ¥14,600,000、Indirect Cost: ¥4,380,000)
Fiscal Year 2015: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2014: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2013: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Outline of Final Research Achievements |
Seborrheic keratosis is one of the most common skin benign tumors in humans with a high occurrence rate in people over 50 years of age. We aimed to evaluate the use of all-trans retinoic acid (ATRA)-loaded microneedle (MN) patches as a simple, alternative therapeutic option to traditional surgical treatments. ATRA-loaded MN patch induced epidermal hyperplasia and marked expression of HB-EGF mRNA and protein corresponding to ATRA activity in the skin of mice. The acceleration of stratum corneum turnover was also observed. In the safety test in human, although the weak positive reaction of erythema due to patch application was identified in all subjects, these reactions disappeared within 30 days. Desquamation of the stratum corneum was observed following four ATRA-MN applications at 1-week intervals, but ATRA-MN applications did not induce severe local or systemic adverse effects.
And we have also developed the novel solid microneedle patch for transcutaneous drug delivery.
|
